{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:10:21Z","timestamp":1791087021795,"version":"4.1.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Se\u0301zary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma.<\/jats:p>","DOI":"10.1182\/blood.v98.9.2865","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:47Z","timestamp":1027759607000},"page":"2865-2868","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":365,"title":["Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report"],"prefix":"10.1182","volume":"98","author":[{"given":"Richard L.","family":"Piekarz","sequence":"first","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Robey","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sandor","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bakke","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Dahmoush","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Kingma","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Turner","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Altemus","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Bates","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019112007261325900_B1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.","volume":"89","author":"Chan","year":"1997","journal-title":"Blood."},{"key":"2019112007261325900_B2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1023\/A:1008439620513","article-title":"Report of the European task force on lymphomas: workshop on peripheral T-cell lymphomas.","volume":"9","author":"Campo","year":"1998","journal-title":"Ann Oncol."},{"key":"2019112007261325900_B3","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts.","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol."},{"key":"2019112007261325900_B4","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood."},{"key":"2019112007261325900_B5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome).","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med."},{"key":"2019112007261325900_B6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7164\/antibiotics.47.301","article-title":"FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, I: taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.","volume":"47","author":"Ueda","year":"1994","journal-title":"J Antibiot (Tokyo)."},{"key":"2019112007261325900_B7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7164\/antibiotics.47.315","article-title":"FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, III: antitumor activities on experimental tumors in mice.","volume":"47","author":"Ueda","year":"1994","journal-title":"J Antibiot (Tokyo)."},{"key":"2019112007261325900_B8","first-page":"627","article-title":"Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.","volume":"46","author":"Lee","year":"1994","journal-title":"Mol Pharmacol."},{"key":"2019112007261325900_B9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/excr.1998.4027","article-title":"FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.","volume":"241","author":"Nakajima","year":"1998","journal-title":"Exp Cell Res."},{"key":"2019112007261325900_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7","article-title":"Histone deacetylases, transcriptional control, and cancer.","volume":"184","author":"Cress","year":"2000","journal-title":"J Cell Physiol."},{"key":"2019112007261325900_B11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer-treatment.","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer."},{"key":"2019112007261325900_B12","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol."},{"key":"2019112007261325900_B13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1271\/bbb.58.1579","article-title":"Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells.","volume":"58","author":"Ueda","year":"1994","journal-title":"Biosci Biotechnol Biochem."},{"key":"2019112007261325900_B14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1054\/bjoc.2000.1327","article-title":"P21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.","volume":"83","author":"Sandor","year":"2000","journal-title":"Br J Cancer."},{"key":"2019112007261325900_B15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.onc.1202059","article-title":"Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression.","volume":"17","author":"Wang","year":"1998","journal-title":"Oncogene."},{"key":"2019112007261325900_B16","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood.V96.4.1490.h8001490_1490_1495","article-title":"Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis.","volume":"96","author":"Koyama","year":"2000","journal-title":"Blood."},{"key":"2019112007261325900_B17","doi-asserted-by":"crossref","first-page":"10860","DOI":"10.1073\/pnas.95.18.10860","article-title":"ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR\/mSin3\/HDAC1 complex.","volume":"95","author":"Wang","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019112007261325900_B18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V94.2.417.414k49_417_428","article-title":"Chromatin remodeling and leukemia: new therapeutic paradigms.","volume":"94","author":"Redner","year":"1999","journal-title":"Blood."},{"key":"2019112007261325900_B19","first-page":"19a","article-title":"Modulation of DAB389IL-2 (ONTAC) cytotoxicity in leukemia and lymphoma by arginine butyrate and all-trans retinoic acid.","volume":"19","author":"Shao","year":"2000","journal-title":"Proc Am Soc Clin Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/9\/2865\/1442813\/h8210102865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/9\/2865\/1442813\/h8210102865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T07:31:57Z","timestamp":1574235117000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/9\/2865\/53469\/Inhibitor-of-histone-deacetylation-depsipeptide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,1]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.9.2865","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11,1]]}}}